Investor Presentation: First Nine Months of 2020
54
Investor presentation
First nine months of 2020
Novo Nordisk®
Across the STEP 1, 3, and 4 trials, a weight loss of 16.9% to 18.2%
was reported for people treated with semaglutide 2.4 mg
STEP 1
Weight
management
Baseline body
weight (kg)
105.3
10
Sema
STEP 3
Weight management
with IBT
105.8
STEP 4
STEP 2
Sustained weight management
From initiation
to 68 weeks
107.2
From randomisation
to 68 weeks¹
Weight management with
T2DM
96.1
99.8
Placebo
Sema
IBT
Sema
+ IBT
Placebo
Sema
Placebo
6.5
Sema
Placebo
Change from baseline
in BW (%)
-5
-10
5
-15
*
-16.9
-20
-2.4
-5.0
-5.2
*
-8.8
-10.6*
-17.6
*
-18.2*
1 The primary endpoint was measured as the change in weight from randomisation (after a 20-week run-in) to week 68.
*Statistically significant, based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies
IBT: Intensive behavioural therapy; Sema: Semaglutide; BW: Body weight; T2D: Type 2 diabetes
-3.1View entire presentation